AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25937505 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced screening and referral using an electronic psychosocial screening
Number of subjects: 0
Study 25937505 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring using the prioritization tool
Number of subjects: 0
Study 24298779 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Neimadian (Extra) and Neiguan (PC 6)
Number of subjects: 120
Study 24298779 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA)
Number of subjects: 120
Study 22187804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amino acid supplementation
Number of subjects: 50
Study 22187804 — intervention group
Group type: COMPARATOR
Intervention: No amino acid supplementation (Control)
Number of subjects: 50
Study 18710603 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange fruit (150 g)
Number of subjects: 129
Study 18710603 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (300 g)
Number of subjects: 129
Study 18710603 — intervention group
Group type: COMPARATOR
Intervention: Juice (in extended dataset)
Number of subjects: 129
Study 18710603 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (as a variable)
Number of subjects: 129
Study 18710603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex, BMI, contraceptive pill use (as variables)
Number of subjects: 129
Study 16513458 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning-dosed travoprost
Number of subjects: 33
Study 16513458 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-dosed travoprost
Number of subjects: 33
Study 16513458 — intervention group
Group type: COMPARATOR
Intervention: Both morning and evening dosings
Number of subjects: 33
Study 12694428 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX+CPC
Number of subjects: 10
Study 12694428 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX
Number of subjects: 10
Study 12694428 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX+NaF
Number of subjects: 10
Study 12694428 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX+ALC
Number of subjects: 10
Study 12694428 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 10
Study 10513853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 80
Study 10513853 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 80
Study 8951977 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg, equivalent to 2‐3 cups of coffee)
Number of subjects: 47
Study 8951977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 1849730 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pyridostigmine 30 mg 8 hourly
Number of subjects: 10
Study 1849730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1849730 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 1.5 mg
Number of subjects: 10
Study 6755527 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate blood-pressure-lowering expectation group
Number of subjects: 0
Study 6755527 — intervention group
Group type: COMPARATOR
Intervention: Delayed blood-pressure-lowering expectation group
Number of subjects: 0
Study 30501915 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive leaf tea (OLT)
Number of subjects: 31
Study 30501915 — intervention group
Group type: COMPARATOR
Intervention: Green tea (GT)
Number of subjects: 31
Study 30114553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sleep bruxism (SB)
Number of subjects: 50
Study 30114553 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 50
Study 27155740 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate androgen-deprivation therapy
Number of subjects: 293
Study 27155740 — intervention group
Group type: COMPARATOR
Intervention: Delayed androgen-deprivation therapy
Number of subjects: 293
Study 24344104 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 1000/400 IU
Number of subjects: 260
Study 24344104 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000/800 IU
Number of subjects: 260
Study 24344104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 22282548 — intervention group
Group type: EXPERIMENTAL
Intervention: Palovarotene 5 mg·day(‐1) for 1 year
Number of subjects: 262
Study 22282548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 20433277 — intervention group
Group type: EXPERIMENTAL
Intervention: Onyx
Number of subjects: 117
Study 20433277 — intervention group
Group type: COMPARATOR
Intervention: N-butyl cyanoacrylate (NBCA)
Number of subjects: 117
Study 18385594 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous naloxone
Number of subjects: 97
Study 18385594 — intervention group
Group type: COMPARATOR
Intervention: Control group (no naloxone)
Number of subjects: 97
Study 15823678 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced Visual Serial Addition Test (PVSAT)
Number of subjects: 50
Study 15823678 — intervention group
Group type: COMPARATOR
Intervention: Paced Auditory Serial Addition Test (PASAT)
Number of subjects: 50
Study 12460292 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Caine peel applied for 20 minutes
Number of subjects: 60
Study 12460292 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Caine peel applied for 30 minutes
Number of subjects: 60
Study 12460292 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Caine peel applied for 60 minutes
Number of subjects: 60
Study 12460292 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied for 20, 30, or 60 minutes
Number of subjects: 60
Study 10503054 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural adjustments in SCI individuals during a bimanual forward-reaching task.
Number of subjects: 0
Study 10503054 — intervention group
Group type: COMPARATOR
Intervention: Able-bodied controls during a bimanual forward-reaching task.
Number of subjects: 0
Study 7477143 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily
Number of subjects: 994
Study 7477143 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 994
Study 7477143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study 1938715 — intervention group
Group type: EXPERIMENTAL
Intervention: Liothyronine (triiodothyronine, T3) for 4 weeks
Number of subjects: 15
Study 1938715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7091635 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate for premedication
Number of subjects: 28
Study 7091635 — intervention group
Group type: COMPARATOR
Intervention: Non-atropine group (no premedication)
Number of subjects: 28
Study 29697455 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Blumgart mattress suture
Number of subjects: 224
Study 29697455 — intervention group
Group type: COMPARATOR
Intervention: Interrupted suture
Number of subjects: 224
Study 28528287 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (300mg b.i.d.)
Number of subjects: 12
Study 28528287 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine combined with verapamil (80mg t.i.d.)
Number of subjects: 12
Study 28528287 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine and MHD enantiomers
Number of subjects: 12
Study 26683986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactotripeptides (10.2 mg/day)
Number of subjects: 40
Study 23404211 — intervention group
Group type: EXPERIMENTAL
Intervention: EVE + EXE
Number of subjects: 143
Study 23404211 — intervention group
Group type: COMPARATOR
Intervention: PBO + EXE
Number of subjects: 143
Study 22479343 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge, Attitude and Practice (KAP) intervention for fall prevention
Number of subjects: 3021
Study 20047626 — intervention group
Group type: EXPERIMENTAL
Intervention: Omron HEM‐907XL
Number of subjects: 509
Study 17530157 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised quantitative morphometry (SQM)
Number of subjects: 452
Study 17530157 — intervention group
Group type: COMPARATOR
Intervention: Quantitative morphometry (QM) using the Eastell‐Melton method
Number of subjects: 452
Study 17530157 — intervention group
Group type: COMPARATOR
Intervention: Quantitative morphometry (QM) using GP-based reference data
Number of subjects: 452
Study 17530157 — intervention group
Group type: COMPARATOR
Intervention: Quantitative morphometry (QM)
Number of subjects: 452
Study 15629218 — intervention group
Group type: COMPARATOR
Intervention: NBD control subjects at 0 ms ISI
Number of subjects: 3
Study 15629218 — intervention group
Group type: COMPARATOR
Intervention: NBD control subjects at 750 ms ISI
Number of subjects: 3
Study 15629218 — intervention group
Group type: EXPERIMENTAL
Intervention: LHD nonfluent aphasic patients at 0 ms ISI
Number of subjects: 3
Study 15629218 — intervention group
Group type: EXPERIMENTAL
Intervention: LHD nonfluent aphasic patients at 750 ms ISI
Number of subjects: 3
Study 15629218 — intervention group
Group type: EXPERIMENTAL
Intervention: RHD patients at 0 ms ISI
Number of subjects: 3
Study 15629218 — intervention group
Group type: EXPERIMENTAL
Intervention: RHD patients at 750 ms ISI
Number of subjects: 3
Study 11753137 — intervention group
Group type: EXPERIMENTAL
Intervention: Promising markers for diagnosis of interstitial cystitis; specific markers not detailed.
Number of subjects: 0
Study 11753137 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric treatment for interstitial cystitis; specific treatments not detailed.
Number of subjects: 0
Study 10426620 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum betaHCG > or = 3.5 multiple of the median
Number of subjects: 192
Study 10426620 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum betaHCG < or = 2.0 multiple of the median
Number of subjects: 192
Study 1574973 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 40
Study 1574973 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone infusion
Number of subjects: 40
Study 1574973 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone combined with midazolam
Number of subjects: 40
Study 3893488 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 1 mg/kg bolus intravenously plus 0.2 mg/kg intravenously over 12 hours
Number of subjects: 40
Study 3893488 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.75 mg intravenously, then disopyramide 2 mg/kg intravenous bolus and 0.4 mg/kg/h intravenously for 10 hours
Number of subjects: 40
Study 31308004 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 92
Study 31308004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 29031409 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-20 mg DSP (Group 1A)
Number of subjects: 2
Study 29031409 — intervention group
Group type: COMPARATOR
Intervention: Sham saline (Group 2A)
Number of subjects: 2
Study 29031409 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-5 mg DSP (Group 1B)
Number of subjects: 2
Study 29031409 — intervention group
Group type: COMPARATOR
Intervention: 15-20 mg DSP (Group 2B)
Number of subjects: 2
Study 26911204 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized lifestyle intervention focusing on healthy lifestyle, diet, exercise, and weight monitoring (4 sessions at 12‐15, 16‐18, 20‐24, and 37 weeks gestation)
Number of subjects: 102
Study 26911204 — intervention group
Group type: COMPARATOR
Intervention: Control group received routine antenatal care
Number of subjects: 102
Study 26911204 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized lifestyle intervention
Number of subjects: 102
Study 26911204 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 25547480 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal hospice caregiving intervention
Number of subjects: 348
Study 24124675 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 1985
Study 24124675 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetics
Number of subjects: 1985
Study 20584994 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 17.5% CO2
Number of subjects: 96
Study 20584994 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 35% CO2
Number of subjects: 96
Study 20584994 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 9% CO2
Number of subjects: 96
Study 20584994 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 0% CO2
Number of subjects: 96
Study 20584994 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of CO2 (all dosages)
Number of subjects: 96
Study 20584994 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction effect of genotype and CO2 dosage
Number of subjects: 96
Study 18175148 — intervention group
Group type: EXPERIMENTAL
Intervention: IVMP (intravenous methylprednisolone pulse), 30 mg/kg/day for 3 days
Number of subjects: 15
Study 18175148 — intervention group
Group type: COMPARATOR
Intervention: Additional IVIG, 2 g/kg/day
Number of subjects: 15
Study 18175148 — intervention group
Group type: EXPERIMENTAL
Intervention: IVMP
Number of subjects: 15
Study 16918262 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab with chemotherapy followed by a year of trastuzumab
Number of subjects: 0
Study 12612206 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural surfactant
Number of subjects: 50
Study 12612206 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 50
Study 12612206 — intervention group
Group type: COMPARATOR
Intervention: Not supplemented with SP‐B
Number of subjects: 50
Study 12612206 — intervention group
Group type: COMPARATOR
Intervention: Infants dying
Number of subjects: 50
Study 12612206 — intervention group
Group type: COMPARATOR
Intervention: Infants in supplemental oxygen on day 28
Number of subjects: 50
Study 10946985 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Day Acuvue
Number of subjects: 127
Study 10946985 — intervention group
Group type: COMPARATOR
Intervention: Focus Dailies
Number of subjects: 127
Study 9260009 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg)
Number of subjects: 120
Study 9260009 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 120
Study 9260009 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms.kg‐1)
Number of subjects: 120
Study 9260009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 8200169 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone
Number of subjects: 47
Study 8200169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone plus IVIG (500 mg/kg on days 1, 2, 3, and 8)
Number of subjects: 47
Study 2455130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 16
Study 2455130 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (C)
Number of subjects: 16
Study 30150756 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival Metadata Analysis Responsive Tool (SMART)
Number of subjects: 0
Study 30150756 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART
Number of subjects: 0
Study 27149595 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback-guided isometric exercises for 3 days a week for 12 weeks
Number of subjects: 36
Study 27149595 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy program
Number of subjects: 36
Study 24750839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment with dexamethasone 0.25‐0.3 mg/(kg·d) followed by oral prednisone tablets 0.5‐1 mg/(kg·d) for 7‐10 days
Number of subjects: 108
Study 24750839 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment with azithromycin and symptomatic therapies
Number of subjects: 108
Study 24750839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment
Number of subjects: 108
Study 23820151 — intervention group
Group type: COMPARATOR
Intervention: Pressure only
Number of subjects: 28
Study 23820151 — intervention group
Group type: COMPARATOR
Intervention: Pressure with fast cooling (‐4°C/min)
Number of subjects: 28
Study 23820151 — intervention group
Group type: COMPARATOR
Intervention: Pressure with slow cooling (‐0.33°C/min)
Number of subjects: 28
Study 20801122 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 75 μg
Number of subjects: 420
Study 20801122 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 150 μg
Number of subjects: 420
Study 20801122 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 300 μg
Number of subjects: 420
Study 20801122 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 600 μg
Number of subjects: 420
Study 20801122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 20801122 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide (all doses)
Number of subjects: 420
Study 19112204 — intervention group
Group type: COMPARATOR
Intervention: Clinical trial group (54 patients)
Number of subjects: 194
Study 19112204 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside clinical trial group (140 patients)
Number of subjects: 194
Study 19112204 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving II line chemotherapy
Number of subjects: 194
Study 16845121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal approach
Number of subjects: 400
Study 16845121 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 400
Study 12671151 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickened formula (carob bean gum)
Number of subjects: 14
Study 12671151 — intervention group
Group type: COMPARATOR
Intervention: Nonthickened formula
Number of subjects: 14
Study 11155493 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (e.g. Jarsin® coated tablets)
Number of subjects: 0
Study 11155493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11155493 — intervention group
Group type: COMPARATOR
Intervention: Other antidepressants
Number of subjects: 0
Study 8873114 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 12
Study 8873114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1468242 — intervention group
Group type: EXPERIMENTAL
Intervention: Audax ear drops
Number of subjects: 50
Study 1468242 — intervention group
Group type: COMPARATOR
Intervention: Cerumol ear drops
Number of subjects: 50
Study 6365002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 12 mg/kg by mouth, 1.5 hours prior to surgery
Number of subjects: 26
Study 6365002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31060836 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FOG) - 1.55 g of EPA + DHA per day for nine weeks
Number of subjects: 51
Study 31060836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PG) - Olive oil capsules
Number of subjects: 51
Study 30592948 — intervention group
Group type: EXPERIMENTAL
Intervention: 37 °C normal saline (NS)
Number of subjects: 24
Study 30592948 — intervention group
Group type: COMPARATOR
Intervention: 25 °C normal saline (NS)
Number of subjects: 24
Study 26686755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 400mg/m² on week one followed by 250mg/m² on week 2-8
Number of subjects: 19
Study 26686755 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 19
Study 24662443 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI with thrombectomy (TB) using an Eliminate catheter (n = 71)
Number of subjects: 141
Study 24662443 — intervention group
Group type: COMPARATOR
Intervention: PPCI without thrombectomy (non-TB) (n = 70)
Number of subjects: 141
Study 24662443 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI with thrombectomy (TB)
Number of subjects: 141
Study 24662443 — intervention group
Group type: COMPARATOR
Intervention: PPCI without thrombectomy (non-TB)
Number of subjects: 141
Study 24662443 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedure ISS volume
Number of subjects: 141
Study 22031232 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Vinorelbine (GemVin)
Number of subjects: 78
Study 22031232 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Carboplatin (GemCar)
Number of subjects: 78
Study 22031232 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Etoposide (GemEto)
Number of subjects: 78
Study 22031232 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Cisplatin (GemCis)
Number of subjects: 78
Study 21030368 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 11849
Study 21030368 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (4.5 or 9 μg)
Number of subjects: 11849
Study 21030368 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (18 μg)
Number of subjects: 11849
Study 21030368 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (36 μg)
Number of subjects: 11849
Study 21030368 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (variable dosing)
Number of subjects: 11849
Study 17956916 — intervention group
Group type: COMPARATOR
Intervention: Advice and Exercise (A&E)
Number of subjects: 350
Study 17956916 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 350
Study 17956916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Shortwave Diathermy (PSWD)
Number of subjects: 350
Study 15875535 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione treatment
Number of subjects: 76
Study 15875535 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional anti-diabetic treatment)
Number of subjects: 76
Study 12195192 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resection
Number of subjects: 79
Study 12195192 — intervention group
Group type: COMPARATOR
Intervention: Open colorectal resection
Number of subjects: 79
Study 10195674 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertussis vaccine
Number of subjects: 801
Study 8658075 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered acidified full fat cow's milk fortified with 15 mg of iron as ferrous sulfate
Number of subjects: 1655
Study 8658075 — intervention group
Group type: COMPARATOR
Intervention: Powdered full fat cow's milk (non-fortified group)
Number of subjects: 1655
Study 8658075 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed group
Number of subjects: 1655